Neuroscience and Biobehavioral Reviews
July 1, 2026
Marcus J. Glennon, Catherine Bird, Prateek Yadav et al.
2 citations
Setting up a psychedelic study can be a long, arduous, and Kafkaesque process. Researchers are faced with a host of challenges in this rapidly evolving field, necessitating a range of considerations that remain largely unstandardised. Many of the complexities inherent to psychedelic research also challenge existing assumptions around, for example, approaches to psychiatric prescribing, the...
JME Practical Bioethics
July 1, 2026
Edward Jacobs, Edward Palmer, Celia J. A. Morgan
Some investigational compounds exist in both regulated clinical pipelines and unregulated street or online markets. Ketamine, psychedelics and cannabis are all under active clinical investigation while remaining accessible, in unregulated form, through illicit channels without clinician oversight. We propose the term parallel-access compounds for this category and argue that it deserves...
Journal of psychopharmacology (Oxford, England)
June 1, 2026
Gabrielle Smith, Timothy Piatkowski, Jason Ferris et al.
1 citation
While research on novel therapeutic applications of ketamine is expanding, particularly in controlled settings, there is limited exploration of its consumption related to self-treatment of psychiatric conditions. This study investigated the characteristics of people who use ketamine and psychedelics for self-treatment of psychiatric conditions, providing insight into patterns of use within this...
J Psychopharmacol
October 27, 2025
David Nutt, Celia J. A. Morgan, David Erritzøe et al.
2 citations
A long, strange trip: Ketamine treatment in psychiatry.
Alcohol and alcoholism (Oxford, Oxfordshire)
May 14, 2025
Hannah Thurgur, Ben Sessa, Laurie Higbed et al.
3 citations
Safety and tolerability data from the first open-label feasibility study of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for alcohol use disorder was recently published. This paper presents a Bayesian analysis of the impact of MDMA-assisted psychotherapy on treatment success, defined as 2-level reduction in the World Health Organization (WHO) drinking risk at the 3 months...
Research Square
May 13, 2025
Eirini K. Argyri, Joy Krecké, Oliver Robinson et al.
2 citations
Abstract Background As the use of psychedelics increases in both therapeutic and non-clinical settings, reports of extended post-experience difficulties have also emerged. While many individuals integrate their experiences effectively, others face persistent challenges. Despite growing recognition of these issues, there is limited research on best practices for mitigating and addressing...
Addiction (Abingdon, England)
April 28, 2025
Rebecca Harding, Tamsin Barton, Maeve Niepceron et al.
14 citations
To report the symptoms and aetiology of ketamine use disorder (KUD), gauge the effectiveness of current treatment services and identify strategies to enhance patient access and outcomes. Mixed-methods, cross-sectional questionnaire. Electronic survey from November 2023 to April 2024. Participants were recruited through snowball sampling, social media and referrals from UK addiction treatment...
Research Square
March 31, 2025
Eirini K. Argyri, Flora Fraser, Stefan Schilling et al.
Abstract Psychedelic substances are increasingly recognized for their potential to catalyse transformative shifts in worldviews. Central to these transformations are states of awe, a self-transcendent, epistemic emotion. This mixed-methods study explored how awe during psychedelic trips relates to lasting changes in boundaries between self and world, and epistemic shifts that follow...
arXiv Preprint Archive
March 28, 2025
Marcus J. Glennon, Catherine Bird, Prateek Yadav et al.
Setting up a psychedelic study can be a long, arduous, and kafkaesque process. This rapidly-developing field poses several unique challenges for researchers, necessitating a range of considerations that have not yet been standardised. Many of the complexities inherent to psychedelic research also challenge existing assumptions around, for example, approaches to psychiatric prescribing, the...
BMJ Open
February 10, 2025
Kathryn Fletcher, Nadine Ezard, Krista J. Siefried et al.
1 citation
Methamphetamine use disorder is a significant public health concern. No pharmacological treatment options currently exist for methamphetamine use disorder, and psychotherapy is only moderately effective. Preliminary evidence suggests that ketamine-assisted psychotherapy produces sustained improvements in substance use and mental health symptomatology. In addition to direct antidepressant...
J Stud Alcohol Drugs
March 22, 2024
David Nutt, Celia J. A. Morgan, Sukhpreet Klaire
This Perspectives piece gives a brief overview on the last 70 years of psychedelic research in relation to the treatment of mental illness with a particular focus on addictions. We briefly precis the work in the 19650s/60s that started following the discovery of LSD. Then we overview research developments over the past twenty years driven by emerging neuroscience on these agents, the rise of...
Addiction
November 2, 2023
Celia J. A. Morgan
1 citation
Given the shifting public perception of psilocybin and associated legal changes, the increase in use observed by Keyes and Patrick is not surprising. The conclusion that this is a rising health concern is not justified by the data, particularly as in this sample non-lysergic acid diethylamide hallucinogen use seems to have increased in a white, educated, relatively higher socio-economic status...
Frontiers in Psychiatry
2023
Simon Ruffell, Nige Netzband, WaiFung Tsang et al.
1 citation
correction
[This corrects the article DOI: 10.3389/fpsyt.2021.687615.].
BJPsych Open
January 18, 2022
Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman et al.
28 citations
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
American Journal of Psychiatry
January 11, 2022
Meryem Grabski, Amy Mcandrew, Will Lawn et al.
169 citations
OBJECTIVE: Early evidence suggests that ketamine may be an effective treatment to sustain abstinence from alcohol. The authors investigated the safety and efficacy of ketamine compared with placebo in increasing abstinence in patients with alcohol use disorder. An additional aim was to pilot ketamine combined with mindfulness-based relapse prevention therapy compared with ketamine and alcohol...
BJPsych Open
December 23, 2021
Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman et al.
180 citations
Background In the past two decades, subanaesthetic doses of ketamine have been demonstrated to have rapid and sustained antidepressant effects, and accumulating research has demonstrated ketamine's therapeutic effects for a range of psychiatric conditions. Aims In light of these findings surrounding ketamine's psychotherapeutic potential, we systematically review the extant evidence on...
Frontiers in Psychiatry
June 9, 2021
Simon Ruffell, Nige Netzband, WaiFung Tsang et al.
74 citations
Ayahuasca is a natural psychoactive brew, used in traditional ceremonies in the Amazon basin. Recent research has indicated that ayahuasca is pharmacologically safe and its use may be positively associated with improvements in psychiatric symptoms. The mechanistic effects of ayahuasca are yet to be fully established. In this prospective naturalistic study, 63 self-selected participants took...
Journal of Psychopharmacology
January 9, 2021
Abigail M. Freeman, Claire Mokrysz, Chandni Hindocha et al.
6 citations
BACKGROUND: While the acute effects of cannabis are relatively benign for most users, some individuals experience significant adverse effects. This study aimed to identify whether variation in schizotypal personality traits and frequency of cannabis use influence the acute effects of delta-9-tetrahydrocannabinol (THC). METHODS: Individual participant data from four double-blind, randomised,...
Frontiers in Psychiatry
2021
Özden Merve Mollaahmetoğlu, Johanna Keeler, Katherine J Ashbullby et al.
62 citations
Background: The therapeutic benefits of ketamine have been demonstrated for a variety of psychiatric disorders. However, the role of ketamine induced psychoactive experiences in mediating the therapeutic effects is unclear. Despite the growing quantitative research on the efficacy of ketamine treatment, very few studies examined participant experiences of ketamine infusions in a treatment...
Behavioural Brain Research
August 17, 2020
Meryem Grabski, Anna Borissova, Beth Marsh et al.
Esketamine was recently licensed by the US Food and Drug Administration (FDA) and European Drug Agency (EDA) for use in treatment resistant depression (TRD), and further research indicates ketamine as a possible treatment in other mental health conditions. While the underlying mechanisms remain unclear, it has been hypothesised that ketamine's acute psychoactive effects may be associated with...
Psychological Medicine
April 28, 2020
Claire Mokrysz, Natacha D. C. Shaban, Tom P. Freeman et al.
24 citations
BACKGROUND: Acute cannabis administration can produce transient psychotic-like effects in healthy individuals. However, the mechanisms through which this occurs and which factors predict vulnerability remain unclear. We investigate whether cannabis inhalation leads to psychotic-like symptoms and speech illusion; and whether cannabidiol (CBD) blunts such effects (study 1) and adolescence...
Journal of Psychopharmacology
February 5, 2019
Molly Carlyle, Tobias Stevens, Leah Fawaz et al.
22 citations
Background: 3,4-Methylenedioxymethamphetamine (MDMA) is widely known for its positive acute effects on social behaviour, such as increasing empathy, whilst also attenuating the negative impact of social exclusion. However there is a scarcity of research that investigates the long-term impact of recreational MDMA use on these fundamental social processes. Method: Sixty-seven individuals were...
Scientific Reports
February 28, 2018
Will Lawn, Jaime E. C. Hallak, José A. Crippa et al.
3 citations
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.
Scientific Reports
November 3, 2017
Will Lawn, Jaime E. C. Hallak, José Alexandre S. Crippa et al.
78 citations
Abstract Ayahuasca is a natural psychedelic brew, which contains dimethyltryptamine (DMT). Its potential as a psychiatric medicine has recently been demonstrated and its non-medical use around the world appears to be growing. We aimed to investigate well-being and problematic alcohol use in ayahuasca users, and ayahuasca’s subjective effects. An online, self-selecting, global survey examining...
The International Journal of Neuropsychopharmacology
August 30, 2017
Tom P. Freeman, Rebecca Pope, Matthew B. Wall et al.
67 citations
Background: Despite the current shift towards permissive cannabis policies, few studies have investigated the pleasurable effects users seek. Here, we investigate the effects of cannabis on listening to music, a rewarding activity that frequently occurs in the context of recreational cannabis use. We additionally tested how these effects are influenced by cannabidiol, which may offset...